RP — Replicel Life Sciences Share News
0.000.00%
Last trade - 00:00- CA$0.74m
- CA$1.19m
- CA$0.35m
Brief: Positive results from Replicel's RCS-01 phase I skin trial are the Company's most compelling to date
Brief: Replicel says rct-01 tendon repair clinical trial shows signs of healing chronic tendon problems
Brief: Replicel's phase 1 clinical trial for hair loss meets primary endpoints
Brief: RepliCel signs two key service partnerships for final prototype manufacturing and testing of its dermal injector
Brief: RepliCel announces granting of 2 patents in Europe
Brief: Replicel Life Sciences amends terms of private placement
Brief: Replicel life sciences says non-brokered private placement of up to 8 mln units
Brief: Replicel Life Sciences continues restructuring with share structure consolidation
Brief: RepliCel therapy for pattern baldness proceeds to clinical trial launch in Japan
Brief: Replicel life sciences announces restructuring
Brief: RepliCel Life Sciences says patent granted for injection device technologies
Brief: RepliCel Life Sciences appoints Lee Buckler as CEO effective Jan. 1 2016